Pegfilgrastim
Ziextenzo is a prescription medication containing the active ingredient pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF). It is used to reduce the risk of infection in patients with non-myeloid cancers receiving chemotherapy that causes low white blood cell counts. This biosimilar medication stimulates the bone marrow to produce more neutrophils, a type of white blood cell essential for fighting infections.
Ziextenzo is a G-CSF medication that helps prevent infections in cancer patients undergoing chemotherapy by boosting white blood cell production.
Key facts at a glance
- RxNorm
- 2260705
- Generic
- Ziextenzo
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Ziextenzo is indicated to reduce the likelihood of infection in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. It is also used to increase survival in patients exposed to myelosuppressive doses of radiation.
Ziextenzo is a biosimilar to Neulasta containing pegfilgrastim, which binds to granulocyte colony-stimulating factor (G-CSF) receptors on hematopoietic progenitor cells in the bone marrow. This binding stimulates the production, proliferation, and activation of neutrophils, thereby reducing the risk of febrile neutropenia.
Ziextenzo is administered as a single subcutaneous injection once per chemotherapy cycle, typically at least 24 hours after chemotherapy. Common side effects may include bone pain and injection site reactions. Serious potential adverse effects include splenic rupture, acute respiratory distress syndrome, and allergic reactions. Patients with known hypersensitivity to pegfilgrastim or filgrastim products should not use this medication.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy